Inflammation and Heart Disease in Men: Beyond Cholesterol

For three decades, cardiovascular risk management focused almost entirely on cholesterol. The recognition that inflammation is an independent, modifiable driver of atherosclerosis, one that explains why many heart attacks happen to people with normal LDL, has reshaped how some cardiologists approach risk, particularly in men with visceral obesity and metabolic syndrome. The lipid hypothesis is not wrong; statins work, and LDL reduction unambiguously reduces cardiovascular events. But the lipid hypothesis is incomplete. A substantial proportion of residual cardiovascular risk, the events that happen despite optimal statin therapy, appears to be driven by inflammatory processes that statins do not fully suppress. Understanding these pathways, and the growing body of evidence for targeting them, is now a relevant part of cardiovascular medicine.

What Inflammation Means Here

The word inflammation covers two very different biological phenomena, and the distinction matters enormously for understanding cardiovascular disease. Acute inflammation is the protective response to injury or infection: redness, swelling, warmth, and pain at a wound site, or the systemic response to bacterial invasion. This inflammation is essential, self-limiting, and generally beneficial. Chronic low-grade inflammation is something else entirely. It is a sustained, sterile activation of inflammatory pathways in the absence of an acute infection or injury, driven by metabolic signals, oxidized lipids, mechanical stress, and other chronic stimuli.

In the context of cardiovascular disease, the relevant process is chronic sterile inflammation within the arterial wall. When LDL particles, particularly oxidized LDL, deposit in the subendothelial space, they trigger macrophage recruitment. These macrophages engulf lipid and become foam cells, the cellular building blocks of atherosclerotic plaques. The inflammatory milieu within developing plaques, sustained by cytokines including interleukin-1 beta (IL-1beta), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha), determines whether plaques remain stable or become vulnerable to rupture. It is plaque vulnerability rather than plaque size alone that predicts acute MI.

The key biomarkers for assessing systemic inflammation in cardiovascular risk contexts are high-sensitivity C-reactive protein (hs-CRP), IL-6, fibrinogen, and lipoprotein-associated phospholipase A2 (Lp-PLA2). Of these, hs-CRP is the most clinically accessible and best validated. Widely accepted thresholds divide cardiovascular risk: hs-CRP below 1 mg/L is considered low risk, 1 to 3 mg/L is intermediate, and above 3 mg/L is high risk for cardiovascular purposes. Values above 10 mg/L typically reflect acute infection or another acute inflammatory process and are not useful for cardiovascular risk stratification because they cannot be interpreted against the chronic baseline.

An important conceptual point: hs-CRP is a downstream marker, not a cause. It is produced by the liver in response to IL-6 signaling, which is itself downstream of multiple inflammatory pathways. High hs-CRP reflects ongoing inflammation somewhere, but the liver does not know whether that inflammation is in the arterial wall, the fat tissue, the gums, or elsewhere. The marker is useful as a signal but does not pinpoint the source.

The hs-CRP Signal in Men

One of the less commonly discussed sex differences in cardiovascular medicine involves baseline hs-CRP levels. Women, on average, have higher baseline hs-CRP than men. Hormonal influences, body composition differences, and immunological factors all contribute to this sex difference. The clinical implication is that interpreting a given hs-CRP value requires awareness of this context. A man with an hs-CRP of 3 mg/L is at higher relative risk than a woman with the same reading, because 3 mg/L represents a larger deviation from the male baseline than it does from the female baseline.

Men with central obesity are a particularly important subgroup. Waist circumference above 40 inches (102 centimeters) in men is associated with metabolically active visceral fat accumulation that chronically elevates inflammatory markers, often in the presence of entirely normal LDL cholesterol. These are the men who appear metabolically unremarkable on a standard fasting lipid panel but carry substantial inflammatory burden. Visceral adipose tissue is not inert; it actively secretes pro-inflammatory adipokines and cytokines, particularly IL-6, which drives hepatic CRP production and sustains the hs-CRP elevation.

The distinction between visceral fat and subcutaneous fat is critical here. Subcutaneous fat, the fat under the skin, is metabolically less active and less inflammatory. Visceral fat, the fat surrounding the abdominal organs, is highly metabolically active, secretes IL-6 and other pro-inflammatory signals, and suppresses adiponectin, an anti-inflammatory adipokine that normally protects endothelial function. Men accumulate visceral fat preferentially over subcutaneous fat, a pattern that accelerates after age 40 as testosterone levels decline. This creates a scenario where a man’s standard risk assessment may understate his true inflammatory burden because the lipid panel looks acceptable while visceral adiposity is silently generating sustained arterial wall inflammation.

The JUPITER Evidence

The JUPITER trial was the trial that formally established elevated hs-CRP as a treatment target rather than just a risk marker. The investigators enrolled 17,802 apparently healthy adults who had LDL cholesterol below 130 mg/dL (a level then considered low enough to defer statin therapy under standard guidelines) but hs-CRP at or above 2 mg/L, indicating elevated inflammation. Participants were randomized to rosuvastatin 20 mg daily or placebo.

The trial was stopped early by the data safety monitoring board at a median of 1.9 years because the statin arm showed a 44% reduction in major cardiovascular events. This was a striking result: people who would not have qualified for statin therapy under the guidelines of the time showed substantial benefit.

Two important limitations deserve acknowledgment. First, the trial was stopped early, which in randomized controlled trials tends to inflate apparent effect sizes. Trials that stop early at a positive result have fewer observed events than they planned for, and this statistical artifact can make benefit appear larger than it would be in a longer, completed trial. Second, rosuvastatin simultaneously lowered LDL by approximately 50% in addition to lowering hs-CRP. The trial cannot separate the contribution of LDL reduction from the contribution of the anti-inflammatory (pleiotropic) effects of the statin. Whether the benefit came from lower LDL, lower inflammation, or both remains genuinely uncertain from JUPITER alone. Statins do have anti-inflammatory effects beyond LDL reduction, but quantifying the independent cardiovascular contribution of that anti-inflammatory effect from JUPITER data is not possible.

Beyond Statins: CANTOS and the IL-1beta Pathway

The CANTOS trial addressed this uncertainty directly by testing an anti-inflammatory drug that has no effect on LDL. The trial enrolled 10,061 patients who had already experienced a myocardial infarction and who had a persistent hs-CRP at or above 2 mg/L despite being on appropriate medical therapy, including statins. These were patients with residual inflammatory risk. They were randomized to three doses of canakinumab, a monoclonal antibody that specifically targets and neutralizes interleukin-1 beta (IL-1beta), versus placebo.

The 150 mg quarterly dose of canakinumab produced a 15% relative risk reduction in the composite cardiovascular endpoint. LDL levels did not change. The trial provided the clearest proof yet of what is now called the inflammation hypothesis of atherosclerosis: that targeting inflammation independently of LDL can reduce cardiovascular events. This was a conceptually important result, because it demonstrated that the benefit of anti-inflammatory therapy is not simply a consequence of secondary effects on lipids.

However, the practical clinical implications of CANTOS are limited. Canakinumab caused a statistically significant increase in fatal infections, including sepsis. Broadly suppressing IL-1beta, a cytokine central to innate immune defense, predictably impairs the ability to fight bacterial infections. Additionally, the drug is priced at approximately $200,000 per year, making it inaccessible as a population-level cardiovascular prevention strategy. The CANTOS trial proved the biology but did not deliver a usable therapy. The scientific value of establishing the inflammation hypothesis was nonetheless substantial, as it redirected attention toward finding safer, more affordable ways to achieve similar anti-inflammatory effects.

Colchicine: From Gout to Cardiology

Colchicine is a natural compound with decades of clinical use in gout and pericarditis. It is inexpensive, has a well-characterized safety profile, and is now one of the more interesting anti-inflammatory agents in preventive cardiology. Its mechanism is distinct from standard anti-inflammatory drugs. Colchicine inhibits tubulin polymerization (interfering with microtubule assembly), which disrupts the function of the NLRP3 inflammasome, the intracellular platform that processes and activates IL-1beta and IL-18. At the low doses used in cardiovascular applications (0.5 mg daily), it targets this specific inflammatory pathway without the broad immunosuppression associated with drugs like canakinumab or corticosteroids.

The COLCOT trial enrolled 4,745 patients who had experienced a myocardial infarction within the preceding 30 days and randomized them to colchicine 0.5 mg daily versus placebo. The median follow-up was 22.6 months.

The colchicine arm showed a 23% relative reduction in the composite cardiovascular endpoint, driven primarily by reductions in urgent coronary revascularization and stroke. This was a meaningful effect in a post-MI population already receiving guideline-directed medical therapy.

The LoDoCo2 trial extended this evidence to patients with established stable coronary artery disease rather than acute presentations. The trial enrolled 5,522 patients with chronic coronary artery disease, randomized them to colchicine 0.5 mg daily versus placebo, and followed them for a median of 28.6 months.

The composite cardiovascular endpoint was reduced by 31% in the colchicine group. This result confirmed that the benefit was not limited to the vulnerable post-MI period but extended to patients with stable, established coronary disease. Together, COLCOT and LoDoCo2 established a body of evidence that some cardiologists now consider sufficient to incorporate colchicine into treatment algorithms for appropriate patients.

Side effects at 0.5 mg are manageable. Gastrointestinal intolerance, primarily diarrhea, affects roughly 5 to 10% of patients and is the most common reason for discontinuation. Rare cases of myopathy have been reported. Some practitioners monitor creatine kinase (CK) levels in patients on colchicine, particularly those also on statins, given the theoretical risk of additive myopathy, though the clinical evidence for significant myopathy risk at this dose is limited. Colchicine has now been incorporated into some international cardiology guidelines for post-MI and stable CAD patients, though its adoption is not yet universal across all major guideline sets.

REDUCE-IT and Omega-3

Inflammation is not the only residual risk pathway beyond LDL, and the REDUCE-IT trial addressed another: elevated triglycerides. The trial enrolled 8,179 patients who were already on stable statin therapy but had elevated fasting triglycerides (135 mg/dL or above) and were randomized to icosapent ethyl (a highly purified prescription preparation of eicosapentaenoic acid, EPA) at 4 grams daily versus placebo.

The icosapent ethyl arm showed a 25% relative reduction in major adverse cardiovascular events, a result that attracted significant attention given the scale of the effect. The mechanism through which prescription EPA reduces cardiovascular risk is actively debated. Proposed mechanisms include triglyceride reduction, anti-inflammatory effects on the arterial wall, stabilization of cell membranes, and reduction in platelet aggregation. The 4 gram prescription dose achieves plasma EPA concentrations far above what standard over-the-counter fish oil supplements can produce, so the REDUCE-IT results cannot be extrapolated to standard supplement use.

One legitimate methodological controversy concerns the placebo. REDUCE-IT used mineral oil as the placebo rather than an inert substance like corn starch. Some analyses suggested that mineral oil may have modestly worsened lipid and inflammatory markers in the placebo group, potentially making the treated group look better by comparison than it would against a truly inert control. This criticism is contested; the REDUCE-IT investigators and independent analysts have argued that the effect size was too large to be explained by placebo interference. The debate has not been definitively resolved. The evidence supports a meaningful benefit from prescription EPA in appropriately selected patients with elevated triglycerides on statins, but the exact magnitude of that benefit remains uncertain.

Visceral Fat as the Inflammation Engine

For many men, the most accessible leverage point for reducing cardiovascular inflammation is the visceral fat depot itself. Visceral adipose tissue is not simply stored energy; it is an active endocrine organ that secretes IL-6, TNF-alpha, leptin, and resistin (all pro-inflammatory), while suppressing adiponectin (anti-inflammatory). The consequence of visceral fat accumulation is a chronically elevated inflammatory state that sustains hs-CRP elevation, promotes endothelial dysfunction, and accelerates plaque progression, all independent of LDL level.

Adiponectin suppression is particularly significant in men with visceral obesity. Adiponectin protects endothelial cells, improves insulin sensitivity, and inhibits foam cell formation in arterial walls. When visceral fat suppresses adiponectin, this protective layer is removed. Leptin, elevated in visceral obesity, promotes oxidative stress and inflammatory cytokine production. The net effect is a tissue environment that accelerates the atherosclerotic process.

The practical implication carries meaningful implications: visceral fat responds well to intervention. Aerobic exercise reduces visceral fat preferentially over subcutaneous fat, and the hs-CRP decline associated with exercise-induced visceral fat reduction is measurable within weeks to months in intervention studies. Caloric restriction, even modest caloric restriction that produces gradual weight loss rather than aggressive dieting, reduces visceral fat and lowers inflammatory markers. Waist circumference is a more useful clinical indicator of visceral fat burden than BMI in men, because two men with identical BMIs can have radically different visceral fat deposits depending on fat distribution pattern.

The Amplifiers: Sleep Apnea, Alcohol, and Gum Disease

Three conditions that are more prevalent in men than women act as inflammatory amplifiers that drive hs-CRP elevation independent of lipid levels. Understanding them is relevant both because they are common and because they are modifiable.

Obstructive sleep apnea (OSA) causes repeated episodes of nocturnal hypoxia, each of which activates nuclear factor kappa-B (NF-kappaB), a central regulator of inflammatory gene expression. The result is elevated TNF-alpha and IL-6, and hs-CRP levels in untreated OSA are typically two to three times higher than in matched controls without OSA. CPAP treatment, which resolves the hypoxic episodes, produces measurable reductions in hs-CRP within weeks of consistent use. In men with elevated hs-CRP and no other obvious explanation, undiagnosed OSA is a common underlying cause.

Alcohol consumption above two drinks per day increases circulating inflammatory markers in most studies. Binge drinking, defined as four or more drinks in a single occasion, causes acute endothelial injury and a transient inflammatory spike. These effects compound over time. Men are statistically more likely than women to drink above low-risk thresholds, making alcohol a modifiable inflammatory contributor in a significant subset.

Periodontal disease, chronic bacterial infection of the gum tissue, sustains systemic IL-6 and CRP elevation through persistent bacteremia and local inflammatory signaling. Multiple small trials have found that treating severe periodontitis reduces hs-CRP, though the evidence base is not sufficient to make specific recommendations about the cardiovascular benefit of dental treatment. The connection is biologically plausible, consistent, and supported by mechanistic data. Men attend dental care less frequently than women, making unrecognized periodontal disease more common in the patient population most likely to benefit from attention to inflammatory burden.

Where the Evidence Sits

The inflammation hypothesis in cardiovascular medicine is no longer theoretical. CANTOS provided proof of concept that targeting inflammation independently of LDL reduces events. COLCOT and LoDoCo2 provided evidence for a practical, affordable tool. JUPITER established that hs-CRP identifies patients who benefit from statin therapy beyond standard LDL thresholds. The framework is established; the clinical challenge is identifying which patients warrant inflammation-directed treatment beyond standard lipid management.

Current evidence most strongly supports colchicine for post-MI patients and patients with stable coronary artery disease who have persistent hs-CRP elevation above 2 mg/L despite optimal statin therapy. The benefit-risk profile of colchicine at 0.5 mg is favorable in this context: it targets the NLRP3-IL-1beta pathway specifically, at doses that do not produce the systemic immunosuppression associated with biologics like canakinumab. Gastrointestinal side effects are the primary limitation.

The Synthesis: Cholesterol Plus Inflammation

The clinical implication of the last decade’s evidence is that cardiovascular risk in men is not fully described by a lipid panel alone. For men with central obesity, metabolic syndrome, elevated triglycerides, or any of the inflammatory amplifiers described above, hs-CRP adds meaningful information. A man with LDL of 100 mg/dL and hs-CRP of 4 mg/L on statin therapy carries residual risk that the LDL value alone does not capture. The evidence base for what to do with that risk is still developing, but the existence of the risk is not in question.

The most accessible interventions for reducing that inflammatory burden are lifestyle-based: reducing visceral fat through sustained aerobic exercise and modest caloric restriction, addressing sleep apnea if present, moderating alcohol, and attending to dental health. These interventions reduce hs-CRP through multiple pathways simultaneously and carry no serious adverse effects. For men who have already experienced a coronary event or who have established coronary disease, the evidence from COLCOT and LoDoCo2 suggests that colchicine at 0.5 mg may be a reasonable addition to guideline-directed therapy, a conversation between the patient and their cardiologist informed by the current evidence and the individual’s risk profile.

The broader message from this body of work is that improving lipids, while important, addresses only part of the biological process that drives atherosclerosis. The inflammatory dimension of that process is measurable, mechanistically understood, and increasingly targetable. For men whose risk profile includes the inflammatory amplifiers that cluster in male physiology, including visceral fat accumulation, sleep apnea, and metabolic syndrome, this expanded view of cardiovascular risk is not a theoretical nicety. It is a practically relevant framework for understanding why their arterial biology looks the way it does and what might be done about it.

The Signal Check is fifteen questions mapping the male cardiovascular risk pattern, including the physiological domains most commonly missed in standard screenings. It produces a specific starting point for your next clinical conversation.